SMYD2 and non-small cell lung carcinoma: Cisplatin resistant NSCLC cells exhibited increased expression of SMYD2 and p53K370me. Mechanistically, SMYD2 inhibition enhanced p53 pathway activity and induced cell apoptosis, with methylation at K370me also decreasing. The study demonstrated the involvement of SMYD2 in cisplatin resistance through regulating p53 pathway via mono-methylation of p53 at K370